Rulonilimab

DB18922InvestigationalProtein Based Therapies

Rulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: F520 · Immunoglobulin g1 (251-glutamine,298-alanine,429-leucine), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal f520 .gamma.1-chain), disulfide with human-mus musculus monoclonal f520 .kappa.-chain, dimer

Resolves to

Compound

UNIIKQA6N2NT4ZCAS2417124-95-7

Targets

Q15116PDCD1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Rulonilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account